These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20620512)

  • 1. Recipient-based approach to tailoring immunosuppression in liver transplantation.
    Kemmer N; Neff G
    Transplant Proc; 2010 Jun; 42(5):1731-7. PubMed ID: 20620512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma?
    Majno P; Giostra E; Mentha G;
    J Hepatol; 2005 Oct; 43(4):577-84. PubMed ID: 16118027
    [No Abstract]   [Full Text] [Related]  

  • 3. [Implications of the immunologic response to the graft in the design of immunosuppressive treatment for liver transplantation].
    de la Mata M; Barrera P; Montero JL; Fraga E; Briceño J; Pozo JC; Solórzano G
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():52-6. PubMed ID: 15195535
    [No Abstract]   [Full Text] [Related]  

  • 4. Liver transplantation at the University of Wisconsin.
    Chin LT; D'Alessandro A; Knechtle S; Pirsch J; Musat A; Odorico J; Becker Y; Lucey M; Sollinger H; Kalayoglu M
    Clin Transpl; 2002; ():207-13. PubMed ID: 12971451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of immunosuppression withdrawal after liver transplantation.
    Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND
    Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
    Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
    Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of liver transplantation.
    Varo Pérez E; Castroagudín JF
    Transplant Proc; 2010 Mar; 42(2):613-6. PubMed ID: 20304206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
    Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
    Toso C; Merani S; Bigam DL; Shapiro AM; Kneteman NM
    Hepatology; 2010 Apr; 51(4):1237-43. PubMed ID: 20187107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma].
    Rubín A; Berenguer M
    Gastroenterol Hepatol; 2013 Jan; 36(1):48-57. PubMed ID: 22578313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular cancer and liver transplantation: a Western experience.
    Lerut J; Julliard O; Ciccarelli O; Lannoy V; Gofette P
    Recent Results Cancer Res; 2013; 190():127-44. PubMed ID: 22941018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract]   [Full Text] [Related]  

  • 15. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
    Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
    Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
    Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation.
    Brunati A; Feruzi Z; Sokal E; Smets F; Fervaille C; Gosseye S; Clapuyt P; de Ville de Goyet J; Reding R
    Pediatr Transplant; 2007 Feb; 11(1):117-9. PubMed ID: 17239135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection.
    Neff GW; Shire N; Ruiz P; O'Brien C; Garcia M; Dela Garza J; Rudich SR; Reddy KR
    Transplant Proc; 2005 Dec; 37(10):4397-402. PubMed ID: 16387130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation: past, present and future.
    Zarrinpar A; Busuttil RW
    Nat Rev Gastroenterol Hepatol; 2013 Jul; 10(7):434-40. PubMed ID: 23752825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunosuppression after liver transplant, now and in future].
    Trunečka P
    Vnitr Lek; 2013 Aug; 59(8):671-7. PubMed ID: 24007221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.